…
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Affimed N.V. is a clinical-stage immuno-oncology company developing innate cell engager therapies designed to recruit and activate natural killer cells and macrophages to kill cancer cells. Long-term growth drivers include clinical progression of its pipeline, potential licensing or partnership deals for its bispecific platform, and increasing interest in innate immune approaches within oncology. The platform's differentiated mechanism and multiple development programs may benefit investors seeking exposure to novel immunotherapies.
The company faces high development and regulatory risk, likely need for external financing with dilution risk, and significant competitive pressure in the immuno-oncology sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -105.94M | -86.00M | -57.52M |
| Net income | -105.94M | -86.00M | -57.52M |
| Selling general administrative | 24.68M | 32.08M | 24.22M |
| Reconciled depreciation | 1.75M | 2.90M | 1.33M |
| Operating income | -111.14M | -88.97M | -65.00M |
| Interest expense | 1.81M | 1.63M | 0.71M |
| Tax provision | 0.00M | 0.00M | 0.00M |
| Interest income | 0.51M | 0.00M | 0.00M |
| Net interest income | 0.24M | -1.27M | -1.13M |
| Total revenue | 8.28M | 41.35M | 40.37M |
| Total operating expenses | 119.41M | 130.33M | 105.36M |
| Total other income expense net | 4.96M | 4.24M | 8.60M |
| Net income from continuing ops | -105.94M | -86.00M | -57.52M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 97.16M | 200.51M | 225.13M |
| Intangible assets | 0.03M | 0.06M | 1.61M |
| Other current assets | 5.50M | 2.46M | 3.53M |
| Total liab | 39.35M | 47.60M | 89.18M |
| Total stockholder equity | 57.81M | 152.91M | 135.95M |
| Capital stock | 1.50M | 1.49M | 1.23M |
| Retained earnings | -536.13M | -430.19M | -333.40M |
| Cash | 38.53M | 190.29M | 197.63M |
| Total current liabilities | 25.91M | 34.65M | 64.55M |
| Short long term debt | 5.83M | 5.93M | 0.58M |
| Total current assets | 84.19M | 196.07M | 206.39M |
| Long term investments | - | 0.00M | 12.35M |
| Short term investments | 34.37M | 0.00M | - |
| Net receivables | 5.33M | 2.70M | 4.81M |
| Long term debt | 6.32M | 11.69M | 17.06M |
| Inventory | 0.46M | 0.63M | 0.42M |
| Accounts payable | 18.92M | 19.08M | 18.86M |
| Non current assets total | 12.97M | 4.44M | 18.74M |
| Capital lease obligations | 7.20M | 0.57M | 1.05M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -33.31M | 6.30M | 0.00M | - |
| Net borrowings | -6.42M | -1.31M | 16.84M | - |
| Total cash from financing activities | -6.22M | 88.56M | 133.58M | - |
| Net income | -105.94M | -86.00M | -57.52M | -41.37M |
| Change in cash | -152.55M | -10.73M | 43.14M | - |
| Begin period cash flow | 190.29M | 197.63M | 146.85M | - |
| End period cash flow | 38.53M | 190.29M | 197.63M | 146.85M |
| Total cash from operating activities | -110.27M | -104.89M | -86.59M | - |
| Issuance of capital stock | 0.23M | 95.91M | 124.46M | - |
| Depreciation | 1.75M | 2.90M | 1.33M | - |
| Change to inventory | 0.10M | -0.21M | -0.17M | - |
| Capital expenditures | 3.73M | 0.70M | 3.85M | 0.00M |
| Change in working capital | -12.16M | -38.07M | -34.81M | - |
| Stock based compensation | 10.71M | 19.11M | 11.82M | - |
| Other non cash items | -0.73M | -2.12M | -6.51M | - |
| Free cash flow | -114.00M | -105.59M | -90.44M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AFMDQ Affimed N.V. |
- -% |
0.00 | - | - | 0.00 | - | 13.07 | 1.13 |
| NVO Novo Nordisk A/S |
-0.34 0.86% |
39.09 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.95 1.30% |
529.50 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-18.50 1.96% |
927.03 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
| Name | Title | Year Born |
|---|---|---|
| Dr. Wolfgang Fischer Ph.D. | MD, COO, Chief Strategy Officer & Member of Management Board | 1964 |
| Dr. Andreas Harstrick M.D. | Chief Medical Officer & Member of Management Board | 1961 |
| Prof. Melvyn Little | Founder & Consultant | NA |
| Mr. Michael Wolf | Head of Finance & Administration | 1967 |
| Mr. Alexander Fudukidis | Head of Investor Relations & Director of Investor Relations | NA |
| Mary Beth Sandin | Vice President of Marketing & Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.